Broad Institute

OCTOBER 16, 2024

William Studier receives the 2024 Merkin Prize in ceremony at the Broad Institute for developing technology used to produce millions of doses of COVID-19 vaccines By Corie Lok October 16, 2024 Breadcrumb Home F. William Studier for development of widely used protein- and RNA-production platform F. Merkin (left) and F.

Vaccine 64

Vaccine RNA Laboratories Molecular Biology 64

Codon

AUGUST 26, 2024

He also explains how they could be used to combat pandemics on “day zero,” well before vaccines are developed. After the outbreak ended, it took another three years for the first Ebola vaccine by Merck to be approved. Timelines for vaccine development are shrinking, but can it move even faster?

RNA 84

RNA Virus DNA Vaccine 84

Drug Target Review

MARCH 21, 2024

Additionally, the COVID-19 RNA vaccines have already demonstrated how safe RNA can be, and we look forward to seeing additional safety data on RNA approaches as the field continues to grow. 2012 Aug 1;181(2):392-400. AAV-based therapies often can’t be dosed more than once due to concerns about an immune response.

Therapies 64

Therapies RNA Immune Response Treatment 64

Codon

MARCH 24, 2024

Water accounts for 70 percent of a bacterium by mass; the other 30 percent includes everything else: proteins, RNA, DNA, lipids, and so on. MenAfriVac is a meningococcal vaccine that remains active, without refrigeration, for up to four days and has significantly boosted vaccine coverage in parts of sub-Saharan Africa.

Engineering 84

Engineering Vaccine Production RNA 84

PLOS: DNA Science

OCTOBER 24, 2024

In those early days, politicians and government officials who’d never heard terms like “cytokine storm” and “RNA virus” were suddenly charged with explaining what was happening. ” Twenty years later, his DYOR fueled the anti-vaccine movement, countering decades of evidence that vaccines work.

Science 52

Science Research Vaccine Government 52

Broad Institute

OCTOBER 4, 2023

Today, scientists use such reactions to produce the customizable DNA and RNA molecules that enable genetic sequencing, drug and vaccine development, pathogen tests, cancer diagnostics, and more. It is because we had the Fellowship that we could buy our very first DNA and RNA synthesizer in the lab.”

DNA 52

DNA RNA Science Protein Expression 52

The Pharma Data

JANUARY 10, 2021

Arcturus Therapeutics got the FDA go-ahead for its Phase II trial of its COVID-19 vaccine candidate ARCT-021. China’s Sinovac Biotech reported that its COVID-19 vaccine, CoronaVac, had a 78% efficacy rate in a Phase III clinical trial in Brazil. The drug is an RNA interference (RNAi) therapeutic. Here’s a look.

Clinical Trials 52

Clinical Trials Trials FDA Vaccine 52